A RESTROSPECTIVE NON-INTERVENTIONAL STUDY AMONG PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS SWITCHING TO FINGOLIMOD OR TO OTHER DISEASE MODIFYING THERAPIES

被引：0
|
作者：
Medin, J. [1 ]
Haddad, P. [2 ]
Ricart, J. [3 ]
Lara, N. [4 ]
Pedros, M. [4 ]
Bizouard, G. [5 ]
Loefroth, E. [1 ]
机构：
[1] Novartis Pharma AG, Basel, Switzerland
[2] Novartis Pharmaceut Canada Inc, Dorval, PQ, Canada
[3] Novartis Farmaceut SA, Barcelona, Spain
[4] IMS Hlth, Barcelona, Spain
[5] IMS Hlth RWE, Boulogne Billancourt, France
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.465
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND12
引用
收藏
页码：A427 / A427
页数：1
相关论文
共 50 条
  • [1] The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis
    Freedman, M. S.
    Duquette, P.
    Grand'Maison, F.
    Lee, L.
    Vorobeychik, G.
    Lara, N.
    Khurana, V
    Nakhaipour, H. R.
    Schecter, R.
    Haddad, P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (05) : 767 - 776
  • [2] The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study
    Lenz, Florian
    Harms, Lutz
    ADVANCES IN THERAPY, 2020, 37 (06) : 2999 - 3009
  • [3] The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study
    Florian Lenz
    Lutz Harms
    Advances in Therapy, 2020, 37 : 2999 - 3009
  • [4] Swiss Analysis of Multiple Sclerosis: A Multicenter, Non-Interventional, Retrospective Cohort Study of Disease-Modifying Therapies
    Gobbi, Claudio
    Zecca, Chiara
    Linnebank, Michael
    Mueller, Stefanie
    You, Xiaojun
    Meier, Rosetta
    Borter, Emmanuela
    Traber, Martin
    EUROPEAN NEUROLOGY, 2013, 70 (1-2) : 35 - 41
  • [5] Disease modifying therapies for relapsing multiple sclerosis
    Wingerchuk, Dean M.
    Weinshenker, Brian G.
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 354
  • [6] KAIROS: A non-interventional study of ofatumumab in patients with relapsing remitting multiple sclerosis who previously received another disease-modifying therapy
    Bischof, Felix
    Groth, Marie
    Redolfi, Josef
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1013 - 1013
  • [7] Switching disease modifying therapies in multiple sclerosis patients: a study of 110 patients
    Morra, VB
    Coppola, G
    Lanzillo, R
    Vacca, G
    Pagano, A
    Orefice, G
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S235 - S235
  • [8] Switching disease modifying therapies in multiple sclerosis patients: a study on 110 patients
    Morra, VB
    Coppola, G
    Vacca, G
    Longobardi, M
    Ascione, S
    Schiavone, V
    Pagano, A
    Bonavita, V
    Orefice, G
    JOURNAL OF NEUROLOGY, 2004, 251 : 88 - 88
  • [9] Switching disease-modifying therapies in multiple sclerosis patients: A study on 110 patients
    Morra, V. Brescia
    Coppola, G.
    Vacca, G.
    Longobardi, M.
    Ascione, S.
    Schiavone, V.
    Pagano, A.
    Bonavita, V.
    Orefice, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 263 - 264
  • [10] Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis
    E. Ann Yeh
    B. Weinstock-Guttman
    Advances in Therapy, 2011, 28 : 270 - 278
12345